Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE.

Mol Cancer. 2009 Jul 14;8:47. doi: 10.1186/1476-4598-8-47.

2.

Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.

Patel MR, Jacobson BA, Belgum H, Raza A, Sadiq A, Drees J, Wang H, Jay-Dixon J, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

J Thorac Oncol. 2014 Aug;9(8):1101-10. doi: 10.1097/JTO.0000000000000214.

3.

SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.

Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, Harran P, Wang L, Brekken RA, Wang X, Minna JD.

Cancer Res. 2011 Dec 15;71(24):7640-8. doi: 10.1158/0008-5472.CAN-10-3947. Epub 2011 Nov 2.

4.

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.

Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, Deri M, Del Tacca M.

Br J Cancer. 2005 Feb 28;92(4):681-9.

5.

Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.

Xie CY, Xu YP, Jin W, Lou LG.

Anticancer Drugs. 2012 Aug;23(7):698-705. doi: 10.1097/CAD.0b013e328352cc10.

PMID:
22441567
6.

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS.

BMC Cancer. 2011 Jun 6;11:221. doi: 10.1186/1471-2407-11-221.

7.

Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.

Li H, Zhu X, Zhang Y, Xiang J, Chen H.

J Exp Clin Cancer Res. 2009 Aug 8;28:110. doi: 10.1186/1756-9966-28-110.

8.

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.

PLoS One. 2010 Nov 29;5(11):e14124. doi: 10.1371/journal.pone.0014124.

9.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA Jr.

Clin Breast Cancer. 2002 May;3 Suppl 1:12-6. Review.

PMID:
12057039
10.

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B.

Carcinogenesis. 2013 Apr;34(4):739-49. doi: 10.1093/carcin/bgs393. Epub 2012 Dec 28.

11.
12.

Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.

Jacob DA, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, Schumacher G, Lippert S, Neumann UP.

J Gastroenterol Hepatol. 2007 May;22(5):738-48.

PMID:
17444865
13.
14.

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.

Gynecol Oncol. 2001 Jun;81(3):380-90.

PMID:
11371126
15.

Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.

Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P, Huang YY, Fong Y, Wong RJ.

Clin Cancer Res. 2008 Mar 1;14(5):1519-28. doi: 10.1158/1078-0432.CCR-07-4628.

16.
17.

Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC.

Clin Cancer Res. 2001 Oct;7(10):3239-50.

18.

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.

Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G.

Cell Cycle. 2013 Mar 15;12(6):877-83. doi: 10.4161/cc.24034. Epub 2013 Feb 21.

19.

Development of docetaxel in advanced non-small-cell lung cancer.

Belani CP, Eckardt J.

Lung Cancer. 2004 Dec;46 Suppl 2:S3-11. Review.

PMID:
15698529
20.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16.

Supplemental Content

Support Center